Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Rizzo, E. Conficoni, M. Palazzini, E. Leci, E. Gotti, G. Mazzanti, F. Terzi, A. Manes, E. Beciani, F. Sciarra, C. Bachetti, F. Sgro‘, N. Galiè (Bologna, Italy). Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects. Eur Respir J 2011; 38: Suppl. 55, 2284

Member's Comments

No comment yet.

Related content which might interest you: Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018 Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 Usefulness of differential blood gas exchange assessment in patients with severe pulmonary arterial hypertension (PAH) associated to congenital heart disease (CHD) Source: Eur Respir J 2005; 26: Suppl. 49, 351s Year: 2005 Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Efficacy of exercise training in congenital heart disease associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Reversibility of increased intrathoracic gas volume and decreased compliance in infants with pulmonary hyperperfusion and hypertension after repair of congenital heart disease Source: Eur Respir J 2005; 26: Suppl. 49, 675s Year: 2005 Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011